CONTEXT: Brief update and short (2min) webcast from Dr Verstovsek on real-world survival data for patients with myelofibrosis taking ruxolitinib. Overall patients saw an increased survival benefit of 1 year plus additional peripheral health benefits | US data only.
IMPACT: Medium
READ TIME: 1 min
Quality Level Mean [1 – 10]: 7
Source URL: https://www.onclive.com/view/dr-verstovsek-on-real-world-survival-data-with-ruxolitinib-in-myelofibrosis